SFT-003

SFT-003 is an investigational inhaled therapeutic candidate being developed by invoX Pharma for the treatment of chronic obstructive pulmonary disease (COPD). The drug is formulated for delivery via the proprietary Softhaler® platform, a high-performance dry powder inhaler (DPI) designed to optimize drug deposition in the lungs and improve patient ease of use. As of early 2024, SFT-003 is in the early stages of development (preclinical). While the specific active pharmaceutical ingredient and its molecular mechanism of action have not been publicly disclosed, the program is a key component of invoX's respiratory pipeline, which focuses on leveraging the Softhaler® technology to enhance the delivery of treatments for obstructive airway diseases.

Other names

SFT-003-IVOXSFT003-IVOXSFT 003-IVOX